@Article{or.2023.028124,
AUTHOR = {QIOU GU, TIAN ZHAN, XIAO GUAN, CHUILIN LAI, NA LU, GUOGUANG WANG, LEI XU, XIANG GAO, JIANPING ZHANG},
TITLE = {Apolipoprotein C1 promotes tumor progression in gastric cancer},
JOURNAL = {Oncology Research},
VOLUME = {31},
YEAR = {2023},
NUMBER = {3},
PAGES = {287--297},
URL = {http://www.techscience.com/or/v31n3/52815},
ISSN = {1555-3906},
ABSTRACT = {Background: Gastric cancer (GC) is a malignancy with the worst prognosis that seriously threatens human
health, especially in East Asia. Apolipoprotein C1 (apoc1) belongs to the apolipoprotein family. In addition, apoc1 has
been associated with various tumors. However, its role in GC remains unclear. Methods: Firstly, we quantified its
expression in GC and adjacent tumor tissues, using The Cancer Genome Atlas (TCGA). Next, we assessed cell
invasion and migration abilities. Finally, we revealed the role of apoc1 in the tumor microenvironment (TME),
immune cell infiltration and drug sensitivity. Results: Firstly, in TCGA database, it has been shown that elevated
expression of apoc1 was identified in various cancers, including GC, then we found that high expression of apoc1 was
significantly correlated with poor prognosis in GC. Histologically, apoc1 expression is proportional to grade, cancer
stage, and T stage. The experimental results showed that apoc1 promoted cell invasion and migration. Then GO,
KEGG, and GSEA pathway analyses indicated that apoc1 may be involved in the WNT pathway and immune
regulation. Furthermore, we found out the tumor-infiltrating immune cells related to apoc1 in the tumor
microenvironment (TME) using TIMER. Finally, we investigated the correlation between apoc1 expression and drug
sensitivity, PD-1 and CTLA-4 therapy. Conclusions: These results suggest that apoc1 participates in the evolution of
GC, and may represent a potential target for detection and immunotherapy in GC.},
DOI = {10.32604/or.2023.028124}
}